: People alive many years after breast (BC) or colorectal cancer (CRC) diagnoses are increasing. This paper aimed to estimate the indicators of cancer cure and complete prevalence for Italian patients with BC and CRC by stage and age. A total of 31 Italian Cancer Registries (47% of the population) data until 2017 were included. Mixture cure models allowed estimation of net survival (NS); cure fraction (CF); time to cure (TTC, 5-year conditional NS >95%); cure prevalence (who will not die of cancer); and already cured (prevalent patients living longer than TTC). 2.6% of all Italian women (806,410) were alive in 2018 after BC and 88% will not die of BC. For those diagnosed in 2010, CF was 73%, 99% when diagnosed at stage I, 81% at stage II, and 36% at stages III-IV. For all stages combined, TTC was >10 years under 45 and over 65 years and for women with advanced stages, but ≤1 year for all BC patients at stage I. The proportion of already cured prevalent BC women was 75% (94% at stage I). Prevalent CRC cases were 422,407 (0.7% of the Italian population), 90% will not die of CRC. For CRC patients, CF was 56%, 92% at stage I, 71% at stage II, and 35% at stages III-IV. TTC was ≤10 years for all age groups and stages. Already cured were 59% of all prevalent CRC patients (93% at stage I). Cancer cure indicators by stage may contribute to appropriate follow-up in the years after diagnosis, thus avoiding patients' discrimination.
Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population‐based study in Italy / Dal Maso, Luigino; Toffolutti, Federica; De Paoli, Angela; Giudici, Fabiola; Francisci, Silvia; Bucchi, Lauro; Zorzi, Manuel; Fusco, Mario; Caldarella, Adele; Rossi, Silvia; De Angelis, Roberta; Botta, Laura; Ravaioli, Alessandra; Casella, Claudia; Musolino, Antonino; Vitale, Maria Francesca; Mangone, Lucia; Fanetti, Anna Clara; Carpin, Eva; Burgio Lo Monaco, Maria Giovanna; Migliore, Enrica; Gambino, Maria Letizia; Ferrante, Margherita; Stracci, Fabrizio; Gasparotti, Cinzia; Carrozzi, Giuliano; Cavallo, Rossella; Mazzucco, Walter; Ballotari, Paola; Ferretti, Stefano; Sampietro, Giuseppe; Rizzello, Roberto Vito; Boschetti, Lorenza; Cascone, Giuseppe; Mian, Michael; Pesce, Maria Teresa; Piras, Daniela; Galasso, Rocco; Bella, Francesca; Seghini, Pietro; Pinna, Pasquala; Crocetti, Emanuele; Serraino, Diego; Guzzinati, Stefano; Null, Null. - In: INTERNATIONAL JOURNAL OF CANCER. - ISSN 0020-7136. - (2024). [10.1002/ijc.34923]
Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: A population‐based study in Italy
Musolino, Antonino;
2024-01-01
Abstract
: People alive many years after breast (BC) or colorectal cancer (CRC) diagnoses are increasing. This paper aimed to estimate the indicators of cancer cure and complete prevalence for Italian patients with BC and CRC by stage and age. A total of 31 Italian Cancer Registries (47% of the population) data until 2017 were included. Mixture cure models allowed estimation of net survival (NS); cure fraction (CF); time to cure (TTC, 5-year conditional NS >95%); cure prevalence (who will not die of cancer); and already cured (prevalent patients living longer than TTC). 2.6% of all Italian women (806,410) were alive in 2018 after BC and 88% will not die of BC. For those diagnosed in 2010, CF was 73%, 99% when diagnosed at stage I, 81% at stage II, and 36% at stages III-IV. For all stages combined, TTC was >10 years under 45 and over 65 years and for women with advanced stages, but ≤1 year for all BC patients at stage I. The proportion of already cured prevalent BC women was 75% (94% at stage I). Prevalent CRC cases were 422,407 (0.7% of the Italian population), 90% will not die of CRC. For CRC patients, CF was 56%, 92% at stage I, 71% at stage II, and 35% at stages III-IV. TTC was ≤10 years for all age groups and stages. Already cured were 59% of all prevalent CRC patients (93% at stage I). Cancer cure indicators by stage may contribute to appropriate follow-up in the years after diagnosis, thus avoiding patients' discrimination.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
